Antiretroviral (ARV)
Overview
In order to contribute to UNAIDS ambitious goal of achieving 95-95-95 by 2030, Aurobindo pharma is expanding through state-of-the-art manufacturing facilities and currently providing latest treatment options to more than 3 million PLHIV & CLHIV in over 125 countries with its antiretroviral drugs.
Aurobindo Pharma is a knowledge-driven company with strong R&D infrastructure to develop generic versions of state-of-the-art latest molecules/treatment options. Our R&D capabilities includes both active pharmaceutical ingredients (APIs) and finished dose formulations (FDFs), thus being a reliable vertically integrated company for assuring uninterrupted global supplies.
Our Commitment
Aurobindo Pharma was the first to develop generic Dolutegravir. Aurobindo Pharma has developed a range of products including combinations and have several other molecules in pipeline for development and commerciallisation.eg. Tenofovir alafenamide, Cabotegravir long-acting injectable/tablet, Paediatric Abacavir/Lamivudine/Dolutegravir etc.
Aurobindo Pharma is one of the few suppliers who have invested in local manufacturing of TLD products in South Africa and have been manufacturing locally for the last five years.
Aurobindo Pharma’s commitment to paediatric HIV is demonstrated through uninterrupted supplies of paediatric solution like Abacavir, Nevirapine & Zidovudine to selected markets, where its still being used for PMTCT and other therapies.
- * PLHIV - People living with HIV
- * CLHIV - Children living with HIV
- * UNAIDS - United Nations Programme on HIV/AIDS
- * LMIC - Low- or Middle-Income Country
- * TLD - Tenofovir, lamivudine, and dolutegravir
- * PMTCT - Prevention of Mother to Child Transmission
- * USFDA - United states Food and Drug Administration
- * ANDA - Abbreviated New Drug Application
- * TLD - Tenofovir, Lamivudine, and Dolutegravir
